Stock Market Edges Higher Ahead Of Fed Minutes; IBD 50 Stock Tops Buy Point; This Stock Soars 65% – Investor's Business Daily

BREAKING: Futures Fall As Market Rally Runs To Key Test

After a promising start to July, the stock market hesitated Wednesday morning as investors faced another set of signals from the Federal Reserve.
Indexes are moving from gains to losses. The S&P 500, Nasdaq and Dow Jones Industrial Average fell 0.1%. The Nasdaq is testing resistance at the 21-day exponential moving average. Small caps lagged, with the Russell 2000 down 0.5%.
Volume rose on the NYSE and Nasdaq compared with the same time on Tuesday.
Indexes made bullish action Friday and Tuesday, erasing big losses to close higher or near session highs. For now, the stock market is holding above the June lows, with its uptrend facing pressure.
Minutes of the Fed’s June meeting are due to be released at 2 p.m. ET. The Fed has made it clear it will continue raising rates to fight inflation, even if it risks a recession. Bond futures trading tracked by the CME’s FedWatch shows more than an 80% chance of a 75-point rate hike at this month’s meeting.
The yield on the 10-year Treasury note continued to drop, down 4 basis points to 2.77%. In a four-day period ending Tuesday, the benchmark yield tumbled nearly 40 basis points. That’s the steepest four-day decline since March 2020, when the Covid crisis rattled financial markets and started a brief bear market.
The price of U.S. crude oil fell 3% to $96.50 a barrel.
DoorDash (DASH) fell 9% and Uber (UBER) nearly 4% after Amazon.com (AMZN) added Grubhub to its suite of Prime services. Under a deal with Grubhub’s parent, Netherlands-based Just Eat Takeaway.com, Amazon also gains the right to acquire a stake in the food-ordering service.
Amazon shares fell 1% in early trading. Just Eat Takeaway.com said it continues to look to sell part or all of Grubhub.
Stocks Rise On Fed Minutes; Two Tesla Rivals In Buy Zones
Innovator IBD 50 ETF (FFTY) rose 0.3%, in line with the stock market indexes. Evolent Health (EVH) broke out above a 33.24 buy point in heavy volume. The buy zone goes to 34.90.
Evolent agreed to acquire IPG, a provider of surgical management technology for musculoskeletal conditions, from an equity platform of alternative asset firm TPG. The deal is worth $375 million plus a contingent consideration of up to $87 million. Evolent, which makes software to help the financial management of medical practices, was profiled in IBD 50 Stocks to Watch on June 22.
Dollar Tree (DLTR) scratched the 166.45 buy point of an oddly shaped cup-with-handle base but is trading slightly below the entry. Volume is flat so far.
Outside the IBD 50, Resolute Forest Products (RFP) shot up 65% after the Canadian paper and lumber products maker agreed to a buyout valued at $2.7 billion. The Paper Excellence Group is buying Resolute through its Domtar subsidiary for $20.50 a share, a 64% premium to Resolute’s closing price on Tuesday. The deal is expected to close in the first half of 2023.
YOU MIGHT ALSO LIKE:
Stock Market Forecast For Next Six Months Holds Big Risks — But Hope Too
Get Free IBD Newsletters: Market Prep | Tech Report | How To Invest
What Is CAN SLIM? If You Want To Find Winning Stocks, Better Know It
IBD Live: Learn And Analyze Growth Stocks With The Pros
MarketSmith’s Tools Can Help The Individual Investor
8/12/2022 See which stocks are showing resilience and strength with an IBD RS Rating upgrade.
8/12/2022 See which stocks are showing resilience and strength with an…
Depression is tricky to treat because the brain remains largely a mystery to researchers. That’s why a cookie-cutter approach to depression treatment doesn’t work. (Jorm S — stock.adobe.com)
Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20!
Get market updates, educational videos, webinars, and stock analysis.
Learn how you can make more money with IBD’s investing tools, top-performing stock lists, and educational content.
Notice: Information contained herein is not and should not be construed as an offer, solicitation, or recommendation to buy or sell securities. The information has been obtained from sources we believe to be reliable; however no guarantee is made or implied with respect to its accuracy, timeliness, or completeness. Authors may own the stocks they discuss. The information and content are subject to change without notice.
*Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade prices are not sourced from all markets.
Ownership data provided by Refinitiv and Estimates data provided by FactSet.
© 2000-2022 Investor’s Business Daily, LLC. All rights reserved

source